Intriguingly, the effects of APOE on amyloidosis appear to be both isoform- and quantity-dependent, as reduction of apoE3 and apoE4 levels through genetic [8, 9] or pharmacologic [10] manipulations results in reduction of cerebral amyloid plaque load. The gene discussed is APOE; the disease is amyloidosis.